| 產(chǎn)品描述： | CP21R7 is potent GSK-3β inhibitor, with an IC50 of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC50 of 1900 nM. |
| 靶點： |
GSK-3β:1.8 nM (IC50);PKCα:1900 nM (IC50);GSK-3;?PKC |
| 體外研究： |
CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC50 of 1.8 nM; the IC50 of CP21R7 against PKCα is 1900 nM. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm |
| 參考文獻(xiàn)： |
1. Gong L, et al. Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. 2. Patsch C, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015 Aug;17(8):994-1003. |
| 溶解性： |
soluble in DMSO |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.151 ml |
15.756 ml |
31.512 ml |
| 5 mM |
0.63 ml |
3.151 ml |
6.302 ml |
| 10 mM |
0.315 ml |
1.576 ml |
3.151 ml |
| 50 mM |
0.063 ml |
0.315 ml |
0.63 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京